Peptide purity testing: what a 99% result can show

What does 99% peptide purity mean?

High-performance liquid chromatography (HPLC) is a test that separates a sample into parts. On many peptide reports, 99% purity means the signal assigned to the intended peptide made up 99% of the measured total. The figure does not say that 99% of the vial's weight is peptide.

Other tests may show how much of the expected material is present. They may also show which impurities were detected, or whether a sample met a stated germ-related requirement.

Each of those tests answers its own question. A result for identity does not prove strength. A purity percentage does not prove sterility.

Sterility means the test found no living microorganisms under stated test conditions. A certificate of analysis does not prove that the tested sample matches the material in a vial, or that the product is FDA-approved.

One test cannot prove the quality of the whole product or how it was made and handled. Drug quality depends on the full system: product design, controlled manufacturing, checked test methods, written limits, process controls, packaging, stability, and tracking. FDA states that testing alone is not enough, because a test usually checks a sample and not every unit in a batch.

The sections below set each testing claim beside what it can show. They give no laboratory procedures, vendor rankings, sourcing advice, or instructions for using a peptide product.

Start with the exact material.

The word “Peptide” names a broad chemical category. It does not identify one molecule, formulation, route, or approved product.

A complete test record names the exact substance, the salt or chemical form where relevant, the dosage form, and the lot or batch number. It also names the container and intended status.

An active pharmaceutical ingredient is the active substance in a medicine. A finished injectable product is a separate item with its own record.

Check whether the report tested the drug substance, an intermediate material from production, or the finished product.

A research-labeled powder, a compounded preparation, and an FDA-approved medicine can share an ingredient name. They can still have different specifications, controls, labels, and evidence.

The first quality question is “what exactly was tested?” A report can answer “was it tested?” and leave that first question open. The tested sample or product should be clear enough to compare with the label and the accompanying records.

A nickname, blend, or marketing category may not identify what was tested. FDA’s peptide guidance work names identity, impurity, and higher-order structure information as needs.

Higher-order structure means the molecule’s three-dimensional shape.

The guidance also names biological-activity information, because peptide quality can involve more than a single mass reading.

Identity testing asks: is this the claimed substance?

Identity testing is meant to distinguish the claimed substance from other substances. For a peptide, that can involve more than detecting a similar mass.

Closely related sequences, truncated chains, modified forms, salts, aggregates, and degradation products may require methods that can discriminate between them. FDA’s Q6A guidance says an identification test should establish the identity of the drug substance and should discriminate between closely related compounds.

A positive identity result has a narrow meaning. The tested portion showed signals consistent with the named material under the stated method. The result does not establish the full impurity profile, biological activity, sterility, stability, or clinical usefulness.

It also does not prove that every container in the lot holds the same material. The identity conclusion is only as strong as the method, the reference standard (known material used for comparison), and the laboratory controls. It also depends on the link between the tested sample and the product under discussion.

Purity is more than one percentage.

A purity result describes how much of the measured signal a method assigned to the intended material. It can also report impurities the method detected. It does not automatically show what share of the sample's total weight is peptide.

Peptide-related impurities can arise during synthesis, purification, handling, or storage. They may include truncated sequences, modified forms, aggregates, residual solvents, degradation products, or other process-related substances.

FDA has noted that peptide impurities can affect safety, effectiveness, and the risk of an unwanted immune response. Full impurity details are part of the purity record for that reason.

A report that says “99% pure” needs more detail. It should give the method, calculation basis, impurity limits, and what makes up the rest of the sample. Limits should cover both named and unnamed impurities. Different methods can produce different percentages.

A high percentage in one separation test does not automatically prove the absence of low-level impurities, microbial contamination, endotoxins, or harmful degradation products.

The percentage is a share of signal in one separation test. It also does not establish that the material performs like an approved medicine in people.

Strength, assay, and activity answer different questions.

Strength, often reported as assay, is the amount of the intended active material in the tested sample. An assay is a test that measures that amount. Strength is a separate result from identity and purity.

A sample can contain the named peptide but have less or more active material than the label states. It can also meet an assay result while containing impurities that require separate evaluation.

For a finished product, strength may also involve concentration, content uniformity, delivered volume, or dose uniformity, depending on the dosage form.

Biological activity is another question. Some peptide products require evidence that the material performs the intended function in a qualified biological or functional assay.

A chemical assay can support the amount without proving receptor activity or clinical effect. A functional signal, in turn, does not independently confirm sequence, purity, sterility, or exact concentration. FDA’s current peptide product guidance work lists biological-activity assessment as one part of a larger quality evaluation.

Sterility and endotoxins cover different risks.

A sterility result does not guarantee that every unit is sterile forever.

USP explains that sterility cannot be demonstrated by testing every unit because the test is destructive. Sterility assurance therefore depends on linked controls, including facility conditions, validated processes, container closure, handling, and appropriate testing.

FDA’s Q6A guidance states that parenteral products should have sterility and endotoxin requirements. Parenteral products are given by injection or another route that bypasses the digestive tract.

Endotoxins are bacterial components that can cause harmful inflammatory reactions even when no living bacteria are detected. A sterility result does not replace an endotoxin result.

Injectable products may also require controls for visible particles and subvisible particles. Subvisible particles are too small to see without special equipment. Controls may also cover pH, container integrity, and stability. These requirements depend on the exact product and route.

A result from a nonsterile research material cannot establish that an injectable finished product is suitable for people.

How to read a certificate of analysis.

A certificate of analysis, or COA, is a record of reported results against stated specifications. A complete COA identifies the material, lot, test date, method or standard, acceptance limit, and observed result.

It also identifies the laboratory or quality unit and the disposition (release or rejection decision).

The word “Pass” tells less than the actual result and limit. A result of “not detected” also needs a method and detection limit. Without those details, the report may be difficult to interpret or compare.

A COA is evidence about the tested sample and the reporting system. By itself, it does not prove FDA approval, manufacturing quality, clinical benefit, or a complete safety review.

Under 21 CFR 211.84, a manufacturer may use a supplier’s report of analysis only with additional identity testing. The manufacturer must also have a process to check the supplier’s reliability. The rule treats accepting a document and checking it independently as separate steps.

Make sure the sample matches the product.

A laboratory result applies to the product only through the link between the tested sample and that product. The sample record should connect the material to a lot, container, collection date, collector, and receiving record.

Federal good manufacturing practice rules require representative sampling. They also require identification of the material, lot number, source container, date, and person who collected the sample. Those details create traceability. They cannot make an unknown sample representative after the fact.

Chain of custody is the documented history of who controlled a sample and when. Breaks can occur when a sample is relabeled, split, stored without a record, or disconnected from the original container.

A genuine-looking PDF can still describe a different lot, a supplier’s retained sample, or a result with no link to the product offered. A matching lot number helps. It should be read together with container records, laboratory identity, report integrity, and storage history.

What testing cannot show.

Testing can reduce uncertainty about defined attributes. It cannot make an unapproved product an approved medicine.

Testing cannot establish that a product suits a particular person, or that evidence for a studied product applies to an unrelated formulation. It cannot establish that a research-labeled material has a proven clinical benefit.

It also cannot replace controls that occur during manufacturing, filling, packaging, storage, and distribution.

A supportable conclusion names what was tested, which method was used, what limit applied, and which lot the result covers. It then states what remains unknown.

If a report does not identify the exact material, lot, method, laboratory, and acceptance criteria, say “cannot confirm from this document.” Do not call the material “safe” or “pure.” For an approved medicine, the current FDA label and a qualified clinician remain the sources for product-specific use and safety decisions.